A61K41/0023

INACTIVATING BACTERIA WITH ELECTRIC PULSES AND ANTIBIOTICS

Provided is a method of reducing a number of viable microbes, including contacting microbes with an antibiotic compound and applying pulses of electricity having a duration of between about 50 nanoseconds and about 900 nanoseconds. The pulses of electricity may have an intensity between about 20 kV/cm and about 40 kV/cm. The pulses of electricity may be applied at a frequency of between about 0.1 Hz and about 10 Hz. The microbes may be a gram-negative or a gram-positive strain of bacteria and the antibiotic may be applied at a concentration for a duration, wherein applying the antibiotic to the strain at the concentration for the duration does not reduce a viable number of bacteria of the strain as much, or at all, when the pulses of electricity are not also applied.

YEAST FOR THE TREATMENT OF ALLERGY
20240066083 · 2024-02-29 ·

A yeast cell for use in the treatment and/or alleviation of allergy and/or symptoms caused by allergy, wherein the yeast cell has been treated with electromagnetic waves in the range of 1 GHz to 300 GHz, or said yeast cell has been grown from a yeast cell treated with electromagnetic waves in the range of 1 GHz to 300 GHz, and composition comprising such a yeast cell.

Methods and systems for activating cells to treat aging
11905510 · 2024-02-20 ·

Harvested stem cells are activated by treating them with an amplitude modulated laser beam having a wavelength lying in the range of 405 to 980 nanometers. The frequency of the laser beam is modulated within a range of 8 to 12 MHz. Using the activated stem cells, tissue can be repaired and regenerated by preparing the unactivated stem cells, treating the unactivated stem cells with an amplitude modulated laser beam having a pre-determined frequency for obtaining activated stem cells, administering the activated stem cells into a body containing the tissue, and using a homing beam to guide the activated stem cells within the body to the location of the tissue.

CHANNELRHODOPSINS FOR OPTICAL CONTROL OF CELLS

The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.

Channelrhodopsins for optical control of cells

The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.

Channelrhodopsins for optical control of cells

The invention, in some aspects relates to compositions and methods for altering cell activity and function and the introduction and use of light-activated ion channels.

SELECTIVE REMOVAL OF AGE-MODIFIED CELLS FOR TREATMENT OF ATHEROSCLEROSIS
20190328876 · 2019-10-31 ·

A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.

Carbon-based surface plasmon source and applications thereof

A spaser device comprises a graphene resonator and a carbon nanotube (CNT) gain element coupled via exciton-plasmon interaction. The graphene resonator may be a rectangular or square graphene nanoflake (GNF), and the CNT gain element may be characterized by chirality vector (n,m) selected such that the CNT has semiconducting properties. The CNT gain element may be illuminated using a light source having a photon energy corresponding with a first exciton energy (E.sub.22) of the CNT, whereby excitons having a second exciton energy (E.sub.11) less than the first exciton energy are generated in the CNT, and coupled to a surface plasmon (SP) mode of the graphene resonator. When the rate of generation of excitons having the second exciton energy exceeds a gain threshold, continuous spasing is established within the spaser device.

METHOD OF ENHANCING ABSORPTION OF INGESTED MEDICAMENTS FOR TREATMENT OF PARKINSONISM
20190307999 · 2019-10-10 ·

A method of using a vibrating gastrointestinal capsule in coordination with an ingestible medicament for treatment of Parkinsonism. The vibrating gastrointestinal capsule, is provided to the subject, and includes: a housing; a vibrating agitation mechanism causing said housing to exert vibrations on an environment surrounding the vibrating gastrointestinal capsule; a power supply for powering said vibrating agitation mechanism; and a control mechanism for activating said vibrating agitation mechanism to operate in said vibration mode of operation. The subject ingests the ingestible medicament and the vibrating gastrointestinal capsule. At least one of a time of ingesting of the vibrating gastrointestinal capsule and a timing or activation delay of the vibration mode of operation is controlled, such that the vibration mode of operation at least partially transpires or completely transpires within an actual or estimated absorption time period of the ingestible medicament within the gastrointestinal tract of the subject.

METHOD OF ENHANCING ABSORPTION OF INGESTED MEDICAMENTS FOR TREATMENT OF AN AILMENT OF THE GI TRACT
20190308002 · 2019-10-10 ·

A method of using a vibrating gastrointestinal capsule in coordination with an ingestible medicament for treatment of an ailment of the GI tract. The vibrating gastrointestinal capsule, is provided to the subject, and includes: a housing; a vibrating agitation mechanism causing the housing to exert vibrations on an environment thereof; a power supply for powering said vibrating agitation mechanism; and a control mechanism for activating said vibrating agitation mechanism to operate in said vibration mode of operation. The subject ingests the ingestible medicament and the vibrating gastrointestinal capsule. At least one of a time of ingesting of the vibrating gastrointestinal capsule and a timing or activation delay of the vibration mode of operation is controlled, such that the vibration mode of operation at least partially transpires or completely transpires within an actual or estimated absorption time period of the ingestible medicament within the gastrointestinal tract of the subject.